Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD4 | P21917 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 14/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14410228 | 0.97 | DRD2 (0.61) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL14410225 | 0.87 | DRD2 (0.49) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL14410226 | 0.87 | DRD2 (0.49) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL10316244 | 0.85 | DRD2 (0.68) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL12400701 | 0.82 | DRD2 (0.72) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL14410230 | 0.82 | DRD2 (0.46) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL14410227 | 0.82 | DRD2 (0.44) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL14046376 | 0.82 | DRD2 (0.75) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL14410178 | 0.82 | DRD2 (0.64) | DRD2DRD4DRD3CCR5KCNH2 | |
| SCHEMBL13801273 | 0.81 | DRD2 (0.67) | DRD2DRD4DRD3CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | DRD2 805/4885DRD4 1703/4885DRD3 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.